Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic pancreatic adenocarcinoma confirmed by histology~* Tumor sample available~* Measurable lesion according to RECIST criteria~* Performance status ≥ 1~* Life expectancy \> 3 months~* Hematology: Hb ≥ 9g/dL, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3~* Renal function: creatinine ≤ 1.5 x ULN~* Hepatic function: total bilirubin ≤ 2.5 x ULN, transaminases ≤ 5 x ULN~* Left ventricular ejection fraction (LVEF) ≥ 50%~* At least a 6-month delay between the end of any previous gemcitabine-based chemotherapy and diagnosis of metastases~* Social security~* Informed consent obtained prior to inclusion.~Exclusion Criteria:~* Non metastatic advanced local disease~* Presence of cerebral metastases or symptomatic leptomeningeal carcinomatosis~* Others cancers except BBC and cervical cancer receiving curative treatment~* No previous treatment by Erlotinib or Trastuzumab~* Known severe hypersensitivity to Erlotinib, Trastuzumab, murine proteins or Gemcitabine~* Presence of significant co-morbidities~* Concomitant treatment with other experimental products or other anticancer therapies~* Breastfeeding or pregnant female, or patient of reproductive age not using adequate contraception~* Legal incapacity or limited legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Gemcitabine - Trastuzumab - Erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).